KR100614504B1 - 임상적 우울증 치료를 위한 디옥시페가닌의 용도 - Google Patents

임상적 우울증 치료를 위한 디옥시페가닌의 용도 Download PDF

Info

Publication number
KR100614504B1
KR100614504B1 KR1020047009851A KR20047009851A KR100614504B1 KR 100614504 B1 KR100614504 B1 KR 100614504B1 KR 1020047009851 A KR1020047009851 A KR 1020047009851A KR 20047009851 A KR20047009851 A KR 20047009851A KR 100614504 B1 KR100614504 B1 KR 100614504B1
Authority
KR
South Korea
Prior art keywords
composition
depression
deoxypeganine
delete delete
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047009851A
Other languages
English (en)
Korean (ko)
Other versions
KR20040068327A (ko
Inventor
요아힘 무어만
헤르만 무케
Original Assignee
하에프 아르쯔나이미텔포르슝 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하에프 아르쯔나이미텔포르슝 게엠베하 filed Critical 하에프 아르쯔나이미텔포르슝 게엠베하
Publication of KR20040068327A publication Critical patent/KR20040068327A/ko
Application granted granted Critical
Publication of KR100614504B1 publication Critical patent/KR100614504B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
KR1020047009851A 2001-12-21 2002-12-14 임상적 우울증 치료를 위한 디옥시페가닌의 용도 Expired - Fee Related KR100614504B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10163667.9 2001-12-21
DE10163667A DE10163667B4 (de) 2001-12-21 2001-12-21 Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
PCT/EP2002/014274 WO2003053445A1 (de) 2001-12-21 2002-12-14 Verwendung von desoxypeganin zur behandlung der klinischen depression

Publications (2)

Publication Number Publication Date
KR20040068327A KR20040068327A (ko) 2004-07-30
KR100614504B1 true KR100614504B1 (ko) 2006-08-22

Family

ID=7710660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047009851A Expired - Fee Related KR100614504B1 (ko) 2001-12-21 2002-12-14 임상적 우울증 치료를 위한 디옥시페가닌의 용도

Country Status (29)

Country Link
US (1) US20050009813A1 (https=)
EP (1) EP1461042B1 (https=)
JP (1) JP2005513105A (https=)
KR (1) KR100614504B1 (https=)
CN (1) CN1283253C (https=)
AR (1) AR037967A1 (https=)
AT (1) ATE404203T1 (https=)
AU (1) AU2002363874B2 (https=)
BR (1) BR0215306A (https=)
CA (1) CA2471338C (https=)
CZ (1) CZ301210B6 (https=)
DE (2) DE10163667B4 (https=)
DK (1) DK1461042T3 (https=)
EA (1) EA006896B1 (https=)
ES (1) ES2312657T3 (https=)
HU (1) HUP0402298A3 (https=)
IL (2) IL162509A0 (https=)
MX (1) MXPA04006125A (https=)
MY (1) MY138088A (https=)
NO (1) NO326446B1 (https=)
NZ (1) NZ533249A (https=)
PL (1) PL370315A1 (https=)
PT (1) PT1461042E (https=)
SI (1) SI1461042T1 (https=)
SK (1) SK287152B6 (https=)
TW (1) TWI241189B (https=)
UA (1) UA76254C2 (https=)
WO (1) WO2003053445A1 (https=)
ZA (1) ZA200404053B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
PT1578422E (pt) * 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
JP5000932B2 (ja) * 2005-06-21 2012-08-15 日東電工株式会社 ニコチン含有経皮吸収製剤
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
CN101433565B (zh) * 2008-11-26 2013-06-05 上海中医药大学 骆驼蓬属种子总生物碱提取物和它们的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit

Also Published As

Publication number Publication date
EP1461042A1 (de) 2004-09-29
NO20042476L (no) 2004-06-14
HK1066742A1 (zh) 2005-04-01
DE10163667A1 (de) 2003-07-10
NZ533249A (en) 2007-05-31
NO326446B1 (no) 2008-12-08
MXPA04006125A (es) 2005-05-16
SI1461042T1 (sl) 2009-02-28
CA2471338A1 (en) 2003-07-03
BR0215306A (pt) 2004-12-21
ATE404203T1 (de) 2008-08-15
SK287152B6 (sk) 2010-01-07
AU2002363874B2 (en) 2007-12-13
CN1283253C (zh) 2006-11-08
US20050009813A1 (en) 2005-01-13
CZ301210B6 (cs) 2009-12-09
IL162509A0 (en) 2005-11-20
CA2471338C (en) 2009-02-24
AR037967A1 (es) 2004-12-22
EA200400751A1 (ru) 2004-12-30
TWI241189B (en) 2005-10-11
EA006896B1 (ru) 2006-04-28
EP1461042B1 (de) 2008-08-13
CN1604781A (zh) 2005-04-06
SK2582004A3 (en) 2004-12-01
PL370315A1 (en) 2005-05-16
IL162509A (en) 2010-06-16
HUP0402298A2 (hu) 2005-02-28
DE10163667B4 (de) 2006-10-26
ZA200404053B (en) 2004-10-12
KR20040068327A (ko) 2004-07-30
ES2312657T3 (es) 2009-03-01
HUP0402298A3 (en) 2011-03-28
AU2002363874A1 (en) 2003-07-09
JP2005513105A (ja) 2005-05-12
UA76254C2 (en) 2006-07-17
WO2003053445A1 (de) 2003-07-03
WO2003053445A8 (de) 2004-07-01
DE50212649D1 (de) 2008-09-25
DK1461042T3 (da) 2008-12-01
CZ2004739A3 (cs) 2004-12-15
TW200301124A (en) 2003-07-01
PT1461042E (pt) 2008-11-03
MY138088A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
US6232326B1 (en) Treatment for schizophrenia and other dopamine system dysfunctions
JP2009517393A (ja) 不安症の治療方法
Bellino et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study
KR100614504B1 (ko) 임상적 우울증 치료를 위한 디옥시페가닌의 용도
JP2005500298A (ja) 嗜癖物質または麻薬に対する依存症を医薬を用いて処置するための活性成分の組み合わせ
BG65735B1 (bg) Приложение на алфа-липоева киселина или нейни прозводни за лечение на мигрена
KR20220054593A (ko) 병용 치료를 위한 화합물
MXPA04006124A (es) Cabeza de cilindro.
US6335372B1 (en) Treatment of obsessive compulsive disorder
CZ355998A3 (cs) Pyridil a pyrimidylpiperaziny pro léčení poruch způsobených odejmutím drogy
US20070292536A1 (en) Composition and method for treating patients with high neurotransmitter levels
Yadav et al. Concise review: Therapeutic potential of flupirtine maleate
MXPA04006126A (es) Acero para herramientas de arranque de viruta.
HK1066742B (en) Use of desoxypeganine for treating clinical depression
US20020099098A1 (en) Method for treating sexual disorders
CN120919140A (zh) 一种艾司氯胺酮与米氮平协同的抗抑郁药物组合物及应用
HK1042238A1 (en) Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group
CN1886127A (zh) 用于治疗精神分裂性精神病的脱氧鸭嘴花碱的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20100812

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110815

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110815